Updates on development of oral remdesivir formulations
Jubilant Pharmova subsidiary Jubilant Pharma has concluded safety and pharmacokinetic/absorption studies of a new oral formulation of remdesivir in animals
Tag: Clinical trial
Use of ivermectin in the treatment of Covid-19: A pilot trial
As repurposing ivermectin against Covid-19 is still in the focus of debates and as this drug can be formulated with
Aequus and reVision to Collaborate on Stargardt Disease Program using SBECD as active
Aequus Pharmaceuticals Inc. and reVision Therapeutics, Inc. (“reVision”) announced a collaboration on the development of a therapy for Stargardt disease.
Mallinckrodt gave up further development of adrabetadex (VTS-270; HPBCD)
Mallinckrodt Pharmaceuticals has reached an agreement to divest and transfer the Investigational New Drug (IND) application for experimental drug adrabetadex
Clinical trial: Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction
CBT-006 is a molecule developed by Cloudbreak Therapeutics that can sequester cholesterol. CBT-006 is a unique topical formulation following 505b(2)
OCULIS ANNOUNCES AN OVERSUBSCRIBED US$57 MILLION SERIES C FINANCING
New leading international life science investors join current institutional investors with proceeds to: Advance novel, late-stage Investigational ophthalmology drugs OCS-01
Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1
Cyclo Therapeutics, Inc., a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and
Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol® Cyclo™ in Alzheimer’s Disease
Cyclo Therapeutics, Inc., a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and
Cyclo Therapeutics Meets Primary Efficacy Endpoint in Phase 1/2 Trial from Intravenous Trappsol® Cyclo™ in Rare Disease Niemann-Pick Type C1 (NPC1)
100% of patients who completed the trial improved or remained stable, and 89% met the efficacy outcome measure of improvement
KAZIA LICENSES CANTRIXIL TO OASMIA
Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company, announced that it has entered into an exclusive worldwide license agreement with